Kornimate/medical-research-clean huggingface dataset:
serum concentration of wnt2 and wnt4 in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: this study aims to find the change of serum wnt effectory moleculars and the association with hs-crp，ctni and prognosis in patients with acute coronary syndrome.

it has been reported that wnt effecory moleculars (wnt2, wnt4, wnt11,wnt10b, dkk1, dkk2) increased in myocardium at acute phase after myocardium infarction in animal experiment. these moleculars can be detected in serum or plasma from human subjects. however, there is few relevant studies about wnt2 and wnt4 concentration in patients with acute coronary syndrome. this study valuates the serum wnt2 and wnt4 concentration in patients with acute coronary syndrome. it will possibly enable to find the relationship between serum wnt2 or wnt4 concentration and hs-crp, ctni and prognosis in patients with acute coronary syndrome.

Eligibility criteria:
inclusion criteria: .diagnosed as acute coronary syndrome, including stemi and nst-acs. * with left ventricular ejection fraction（lvef）\>=45% * written informed consents are obtained * admitted within 24 hours after chest pain attacked exclusion criteria: * • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction * with acute or chronic infection, surgery or trauma in the last month * secondary hypertension, severe liver dysfunction,severe renal insufficiency * with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent

Keywords: wnt signaling
oct guided magmaris rms in stemi

Conditions: STEMI

Summary: percutaneous treatment of coronary artery disease depends on the implantation of stents within diseased coronary segments. compared with conventional bare-metal and drug- eluting stents, which remain permanently within the coronary anatomy, bioresorbable scaffolds (brs) offer several potential advantages due to its resorbable properties. the resorbable magnesium scaffold magmaris has demonstrated favourable outcomes in patients with stable coronary artery disease. in particular, in comparison to polymeric bioresorbable scaffolds, no cases of stent thrombosis have been reported in over two years of follow-up suggesting that magnesium-based resorbable scaffolds have low thrombogenicity and might be particularly beneficial for patients presenting with st- segment myocardial infarction. a recent pilot study in eighteen patients supports this concept, which has led to the development of the proposed prospective multicentre study including intra-coronary imaging with long-term clinical follow-up.


Eligibility criteria:
inclusion criteria: 1. patients presenting with a st-elevation myocardial infarction (stemi) with symptoms onset \<24 hours or with ongoing symptoms. 2. signed patient informed consent. exclusion criteria: 1. age \ 70 years. 2. pregnancy or breastfeeding. 3. cardiogenic shock. 4. creatinine clearance ≤30 ml/min/1.73 m2 (as calculated by mdrd formula for estimated gfr) and not on dialysis. note: chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance. 5. infarct-artery reference diameter \ 4.0 mm (within the segment of the culprit lesion) by visual estimation, and oct infarct-artery distal reference mean lumen diameter \ 3.7 mm 6. non-optimal vessel preparation after predilatation: residual stenosis \>30%. 7. culprit lesion length \> 21 mm. 8. culprit lesion located within a previously stented segment (stent thrombosis or in-stent restenosis). 9. culprit lesion involving a saphenous vein graft. 10. culprit lesion involving a bifurcation with an intended two-stent implantation strategy. 11. ostial right coronary artery 12. severe calcification or tortuosity of the infarct-related artery. 13. absolute contraindication to a 12 months dual antiplatelet therapy. 14. life expectancy \< 3 years. 15. patients taking oral anticoagulant therapy
effect of ketamine in depressive symptoms of elderly patients with visual impairment.

Conditions: Depression in Old Age; Ketamine

Summary: the prevalence of depression in elderly is from 4 to 30% and is associated with a lower quality of life mayor medical comorbidity, and increased mortality. although there are various treatments for depression in the elderly, the study of interventions in resistant depression is limited and there are few reports of the efficacy and safety profile of alternative interventions such as ketamine in the elderly. the final objective of the present study is to report the effects of a single infusion of ketamine on the depressive symptoms in patients undergoing ophthalmologic surgery

the final objective of the present study is to report the effects of a single infusion of 0.5 mg / kg ketamine in infusion on depressive symptoms assessed using the scale yesavage's abbreviated geriatric depression scale. this is a randomized double-blind follow-up study in patients over 60 years of age with ocular pathology who required ophthalmological surgery with retrobulbar block and conscious sedation with ketamine. the sample consisted of two groups: a control group and an experimental group with ketamine. the dose used for the study was 0.5mg / kg in slow infusion for two hours. in both groups the yesavage's questionnaire was applied at three different times; basally, at the end of the recovery and at 24 hours after the surgery.

Eligibility criteria:
inclusion criteria: * men and women aged 60 years or older who due to the severity of visual disability required to be operated on for eye surgery using retrobulbar block * intraocular pressure \<20 mm hg and * asa functional capacity from i to iii exclusion criteria: * previous antidepressants medications * cognitive impairment was found according to the short portable mental status questionnaire (spmsq) assessment * in case of a history of psychosis, schizophrenia, nephropathy * they had a history of difficulties to control arterial blood pressure, uncontrolled hepatic disorders or had a history of adverse response to ketamine according clinical records
coronary heart disease risk factors in blacks vs whites

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases

Summary: to use data from the epidemiologic follow-up study of the national health and nutrition examination survey (nhanes) to develop models to predict morbidity and mortality as a function of risk factors for coronary artery disease. bivariate dependent survival distributions were examined.

the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
immunological profile for patients treated with car-t cells

Conditions: Hematologic Neoplasms

Summary: in the frame of si-cart study, blood will be collected from patients treated with car-t cells: before (at day (d)-6 and d0 before cells injection), post infusion at d3, d5,d7, d9, d11, d14, d18, d 21, month (m) 2 and m12 post injection. a cerebrospinal fluid sample will also be collected if a cerebrospinal fluid analysis lumbar puncture is performed


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * planned injection of car-t cells within the scope of marketing authorization * signed informed consent * french social security affiliation exclusion criteria: * pregnant women, or women of childbearing potential (without medically acceptable contraception) or breastfeeding women. * patient in emergency situation, adult under legal protection (patient placed under tutorship, curatorship, or judicial protection) or unable to give his consent * impossibility to comply with trial medical follow-up for geographic, social or psychological reasons

Keywords: car-t cells immunological profile
cognitive outcomes after brain substructure-informed radiation planning in pediatric patients

Conditions: Brain Tumor; Head and Neck Cancer

Summary: the goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients. patients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and mri imaging (both research and for regular care) done as part of their participation in the study. survivors of childhood brain tumors who completed radiation therapy at least two years before joining the study, and have not had a recurrence, will have neurocognitive testing and research mris completed. healthy children will also be enrolled and have research mris done. the researchers will use the radiation plan to determine how much radiation was delivered to different parts of the brain. the investigators will use the mris to determine how the normal brain is changing after treatment; and how this compares to patients who had standard radiation treatment or who never had a brain tumor. the neurocognitive testing will be compared among different groups to see how different treatment plans affect performance on neurocognitive tests.


Eligibility criteria:
1. stratum a 1. eligibility criteria * aged 1 to \<26 years of age * tumor must be located in the brain or adjacent to the brain including but not limited to nasopharynx, paranasal sinuses and orbit * treatment must include radiation therapy (either proton or photon) * patients must not have completed radiation therapy 2. exclusion criteria * pregnancy * patients who are not able to undergo neuro-cognitive testing, including children lacking english comprehension or children with premorbid neurological/neurodevelopmental disorders such as down's syndrome or autism 2. stratum b 1. eligibility criteria * diagnosed with a brain tumor at \<26 years of age * received radiation to the brain as part of therapy * time from radiation start to study enrollment is ≥ 2 years * there has not been disease recurrence from time of most recent radiation treatment to study enrollment 2. exclusion criteria * patients who are not able to undergo neuro-cognitive testing, including children lacking english comprehension or children with premorbid neurological/neurodevelopmental disorders such as down's syndrome or autism 3. stratum c 1. eligibility criteria * must be aged 5 to \<26 years of age * must be able to complete research imaging without sedation 2. exclusion criteria * must not have any major psychiatric, neurologic or medical diagnosis

Keywords: radiation therapy pediatric
apatinib + ifosfamide and etoposide for relapsed or refractory osteosarcoma

Conditions: Effect of Drug; Toxicity, Drug; Secondary Resistance

Summary: today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic polychemotherapy followed by local surgical therapy and then postoperative (adjuvant) chemotherapy, long-term, disease-free survival can be achieved in 60- 70% of osteosarcoma patients. however treatment options for osteosarcomas, especially in the setting of metastatic or unresectable disease, are very scarce. apatinib has been proved to be an effective agent to prolong progression-free survival in advanced osteosarcoma. but after 4-6 months' treatment, secondary resistance always occurred with musculoskeletal lesions' progression or new metastasis. nowadays giving therapeutic doses of ie concurrently with anti-angiogenesis tyrosine kinase inhibitors is a conceptually attractive strategy for treating patients with refractory osteosarcoma according to prospective trial of lenvatinib +ie reported by gaspar et al at 2019 esmo and 2020 esmo. thus this study was designed to review our experience in real world for off-label use and characterize the toxicity profile of concurrent apatinib+ie and ie alone in patients with relapsed or refractory osteosarcoma.


Eligibility criteria:
inclusion criteria: * histological diagnosis of osteosarcoma (confirmed by central pathological review by an expert pathologist from the peking university people's hospital) * objective disease progression within 3 months prior to treatment according to recist 1.1 * previously treated with one to two lines of chemotherapy for metastatic disease * have an adequate performance status (adults:eastern cooperative oncology group \[ecog\] performance status of 0-1;children aged \>12 years: a score of ≥60% on the karnofsky performance scale; children aged ≤12 years a score of ≥60% on the lansky scale) exclusion criteria: * a life expectancy of less than 3 months * patients had to have adequate bone marrow function, normal renal function, normal liver function, and normal pancreatic function * no other malignant tumors * no malignant pleural and peritoneal effusion

Keywords: osteosarcoma apatinib ifosfamide and etoposide prognosis toxicity
brief interventions for short-term suicide risk reduction in military populations

Conditions: Suicide; Suicidal Ideation

Summary: the purpose of the proposed study is to identify the most effective brief interventions for reducing short-term risk for suicide attempts in "real world" military triage settings, and to identify potential mechanisms of change underlying the interventions' impact on subsequent suicide attempts. we will randomize 360 patients to one of three commonly-used crisis interventions delivered as routine care in the mental health triage system: (1) treatment as usual (tau); (2) standard crisis response plan (s-crp); or (3) enhanced crisis response plan with reasons for living (e-crp). the following hypotheses will be tested: 1. the enhanced crisis response plan (e-crp) intervention will contribute to significantly decreased risk for suicide attempts and hospitalization during follow-up relative to the standard crisis response plan alone (s-crp) and treatment as usual (tau). 2. the standard crisis response plan (s-crp) intervention will contribute to significantly decreased risk for suicide attempts and hospitalization during follow-up relative to treatment as usual (tau). 3. greater ambivalence about suicide and faster recall of reasons for living will mediate the relationship between intervention and reduced risk for suicide attempt during follow-up.

the crp has been proposed as an alternative to tau for the short-term management of suicidal patients and is now in widespread use, but has never been empirically tested. the crp is purported to reduce suicide risk via unique mechanisms that directly suicide risk, notably suicidal ambivalence (i.e., the relative balance between the wish to live and the wish to die) and problem solving. because suicidal ambivalence has gained support as an active mechanism for reducing suicide risk, the present study will also seek to augment this underlying mechanism by directly engaging the suicidal patient in a discussion about their reasons for living, thereby potentially increasing the potency of the crp. the present study therefore entails a component analysis of crisis interventions. as such, we anticipate ordered effects, whereby the s-crp and e-crp conditions will show significantly better outcomes than tau, and e-crp will demonstrate significantly better outcomes than the standard crp condition.

Eligibility criteria:
inclusion criteria: * active duty * 18 years of age or older * reporting current suicidal ideation with intent to die, or a suicide attempt within the past two weeks * able to speak and understand the english language * able to complete the informed consent process exclusion criteria: * severe psychiatric or medical conditions that preclude the ability to provide informed consent or participation in outpatient treatment

Keywords: suicide suicidal ideation ambivalence suicide ambivalence reasons for living reasons for dying military veteran clinical trial cognitive behavioral therapy psychotherapy crisis treatment as usual (tau) crisis response plan (crp) enhanced crisis response plan (e-crp)
randomized controlled trial: induction of labour of obese women with dinoprostone or single balloon catheter

Conditions: Obesity; Pregnancy; Labor, Induced

Summary: the purpose of this study is to compare the efficacy of single balloon foley catheters to dinoprostone for the induction of labour of obese women. the investigators suspect that women assigned to the foley group will have a shorter induction to delivery time than women in the dinoprostone group.


Eligibility criteria:
inclusion criteria: * obese (bmi \>30 before 20 weeks gestational age) * singleton pregnancy * vertex presentation * bishop score \<6 * intact membranes * gestational age 37+0 to 42+0 * normal fetal heart tracing on admission for ripening exclusion criteria: * induction of labour for intrauterine fetal demise * intrauterine growth restriction * suspected abruption at the start of induction * any contraindication for a vaginal delivery

Keywords: obesity labor, induced pregnancy cervical ripening dinoprostone
a clinical trial to evaluate the safety and efficacy of 20 ml cerebrolysin in patients with vascular dementia

Conditions: Vascular Dementia

Summary: this clinical trial was performed to assess the clinical efficacy and safety of two 4 week treatment courses of daily intravenous administration of cerebrolysin (20ml \[milliliter\] iv \[intravenous\] per day). the study was performed as prospective, randomised, double-blind, placebo-controlled, parallel group, multicentre study with 2 study groups. group 1: 20 ml cerebrolysin and 100 mg (milligram) acetylsalicylic acid group 2: placebo (0.9% nacl \[sodium chloride\]) and 100 mg acetylsalicylic acid the study drug was given once daily by intravenous infusion (20ml in 250ml saline solution) for 4 weeks on five consecutive days per week. this treatment regimen was repeated after a two-month treatment-free interval. acetylsalicylic acid was given orally, once daily throughout the study duration of 24 weeks. altogether five clinical evaluation visits at baseline (day 0) and at week 4, 12, 16, and 24 were necessary.


Eligibility criteria:
inclusion criteria: * men or post-menopausal women between 50 and 85 years * clinical diagnosis of vascular dementia according to ninds-airen criteria * ct or mri results compatible with clinical diagnosis * mmse score between 10 and 24, both inclusive * modified hachinski ischemic score \>4 * hamilton depression scale score of less than or equal to 15 * adequate visual and auditory acuity to allow neuropsychological testing * informed consent given by the patient and/or the next-of-kin exclusion criteria: * gastric ulcer associated with intolerance of acetylsalicylic acid treatment * severe psychotic features, schizophrenia, depression, agitation or behavioral problems within the last three months that could lead to difficulty complying with the protocol * any severe systemic illness or unstable medical condition that could lead to difficulty complying with the protocol or significantly limits life span. * patients who in the investigator's opinion, would not comply with study procedures * any significant neurological disease other than vascular dementia, such as parkinson's disease, epilepsy, huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis * history of alcohol or substance abuse or dependence within the past two years * patients with a history of systemic cancer within the past two years * severe congestive heart failure or malignant, uncontrollable hypertension * participation in a clinical trial with an investigational drug in the past four weeks
cephalic vascular recording upon spg stimulation

Conditions: Chronic Cluster Headache

Summary: hypothesis: stimulation of the spg at high frequencies (50-200hz) is believed to cause a physiological parasympathetic block which decreases vmca oxyhb concentration and cephalic vessel diameter. stimulation of the spg at low frequencies (1-60 hz)is believed to cause a physiological parasympathetic upregulation which increases vmca, oxyhb concentration and cephalic vessel diameter.

efferent

Eligibility criteria:
inclusion criteria: •subject is currently enrolled in pathway ch-1 (cip-001) exclusion criteria: •subject is not currently enrolled in pathway ch-1(cip-001)

Keywords: chronic cluster headache
efficacy and safety of biocellulose sheet containing anti-hyperpigmentation agent ("biocellulose mask", "farhorm®") in patients receiving laser treatment

Conditions: Skin Pigmentation; Skin Irritation

Summary: the laser areas treated with biocellulose sheet from coconut juice containing anti-hyperpigmentation agent ("biocellulose mask", "farhorm®") heal faster than vaseline ointment which is a standard treatment.

volar surface at upper arm (2x2 cm) on both sides were treated with semi ablative, 1,550 nm erbium: glass fractional laser. biocellulose sheet from coconut juice containing anti-hyperpigmentation agent ("biocellulose mask","farhorm®")was applied for 20 min on one side and the other side was treated with vaseline ointment. the redness, skin hydration and skin pigmentation were evaluated at that area before laser, immediately after laser and after applying the treatment. these parameters were compared between treatment (area treated with biocellulose sheet from coconut juice containing anti-hyperpigmentation agent, "biocellulose mask", "farhorm®") and control (vaseline ointment).

Eligibility criteria:
inclusion criteria: * age 20-50 years old * no skin problem such as inflammation, fresh wounds * not receive laser treatment during last 3 months * no history of smoking or alcohol drinking * no allergy to licorice extract, vit c, vit e, arbutin or stearyl glycyrrhetinate * willing to participate in this study and can comply with study protocol exclusion criteria: * has history of hyperallergic reaction * has wound(s) on face during last 4 weeks * has history of eczema, psoriasis during last 6 months * has laser treatment during last month * use steroid, antibiotic, anti-inflammatory drugs or antihistamine during 3 days before recruiting * had major surgery during last 12 months * has history of cancer during last 12 months * pregnant or lactation